Treatment Group for Vomiting

Phase-Based Progress Estimates
Gabrail Cancer Center Research, Canton, OH
Vomiting+1 More
All Sexes
What conditions do you have?

Study Summary

This is a repeat-dose, single-arm, open-label study that will evaluate the potential impact of subject-reported injection-site reactions (ISRs) on activities of daily living (ADL) in adult subjects with cancer receiving SUSTOL® (granisetron) extended-release injection, for subcutaneous use for prevention of chemotherapy induced nausea and vomiting (CINV) for up to 4 sequential cycles of chemotherapy (Moderately Emetogenic Chemotherapy [MEC] or Anthracycline and Cyclophosphamide [AC] combination regimen).

Eligible Conditions

  • Vomiting
  • Chemotherapy-Induced Nausea and Vomiting (CINV)

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 14 days

14 days
Number of subjects with potential impact of subject-reported ISRs on ADL in adult subjects with cancer administered SUSTOL.

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

1 Treatment Group

Treatment Group
1 of 1
Experimental Treatment

300 Total Participants · 1 Treatment Group

Primary Treatment: Treatment Group · No Placebo Group · Phase 4

Treatment Group
Experimental Group · 1 Intervention: SUSTOL · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 14 days
Closest Location: Gabrail Cancer Center Research · Canton, OH
2016First Recorded Clinical Trial
3 TrialsResearching Vomiting
45 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a life expectancy of greater than 6 months.
You are able to receive dexamethasone for the prevention of emesis.
You are scheduled to receive MEC or AC regimen for at least 4 cycles of chemotherapy, and are prescribed SUSTOL for CINV prevention.
You have a performance status of 0 or 1.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.